The quest for excellence (part 2): reviewing a clinical trial for the British Journal of Dermatology
One hundred and twenty-five years and counting: into an era of systems dermatology
Rosacea, the face of innate immunity
Screening for infections prior to initiating immunosuppressive treatment for patients with autoimmune blistering diseases
Which HOME for atopic dermatitis?
Third time coming HOME: not just EASI
Human sebocytes: the new leptin connection?
Ultraviolet involvement in melanocyte transformation to melanoma
Update: advanced methods in three-dimensional organotypic tissue engineering for congenital ichthyosis and other rare keratinization disorders
A peptide from a gastric pathogen for the treatment of acne
Melanoma excision: how deep must we go?
Hand eczema – a chronic condition with far-reaching consequences
Hidradenitis suppurativa outcome measures and treatment goals
Essential inputs for studies of cost-effectiveness analysis in melanoma
Alcoholic drinks and skin cancer – boozing on the beach and beyond
A telephone-based motivational interviewing intervention has positive effects on psoriasis severity and self-management: a randomized controlled trial
Vitamin D and photodermatoses
Photodynamic therapy: increasing acceptance through reduction of adverse reactions
Penicillin to prevent recurrent leg cellulitis: a critical appraisal
Author response to van Zuuren et al ., Penicillin to prevent recurrent cellulitis: a critical appraisal
Preventing cellulitis: where next?
Evidence-based guidelines for laboratory screening for infectious diseases before initiation of systemic immunosuppressive agents in patients with autoimmune bullous dermatoses
Report from the third international consensus meeting to harmonise core outcome measures for atopic eczema/dermatitis clinical trials (HOME)
Leptin promotes a proinflammatory lipid profile and induces inflammatory pathways in human SZ95 sebocytes
Cell fate regulated by nuclear factor-κB- and activator protein-1-dependent signalling in human melanocytes exposed to ultraviolet A and ultraviolet B
A mouse organotypic tissue culture model for autosomal recessive congenital ichthyosis
Inhibitory and anti-inflammatory effects of the Helicobacter pylori -derived antimicrobial peptide HPA3NT3 against Propionibacterium acnes in the skin
Ultraviolet filter contact and photocontact allergy: consumer exposure and risk assessment for octocrylene from personal care products and sunscreens
Occupational allergic contact dermatitis and major allergens in France: temporal trends for the period 2001–2010
The risk of bacteria in foam sclerotherapy: does the condition of the air in outpatient vs. operating rooms make a difference?
Excision of fascia in melanoma thicker than 2 mm: no evidence for improved clinical outcome
Histopathological findings in cutaneous small-vessel vasculitis associated with solid-organ malignancy
Spectrum of cutaneous manifestations of type 1 diabetes mellitus in 500 south Asian patients
Filaggrin loss-of-function mutations and incident cancer: a population-based study
Prevalence of actinic keratosis among dermatology outpatients in Austria
The Hidradenitis Suppurativa Priority Setting Partnership*
Hand eczema – prognosis and consequences: a 7-year follow-up study
Assessing the validity, responsiveness and meaningfulness of the Hidradenitis Suppurativa Clinical Response (HiSCR) as the clinical endpoint for hidradenitis suppurativa treatment
Health-related quality of life in patients with melanoma expressed as utilities and disability weights
Alcohol intake and early-onset basal cell carcinoma in a case–control study
A telephone-based motivational interviewing intervention has positive effects on psoriasis severity and self-management: a randomized controlled trial
Safety and efficacy of calcipotriol plus betamethasone dipropionate gel in the treatment of scalp psoriasis in adolescents 12–17 years of age
Sunlight exposure behaviour and vitamin D status in photosensitive patients: longitudinal comparative study with healthy individuals at U.K. latitude
Topical corticosteroid reduces inflammation without compromising the efficacy of photodynamic therapy for actinic keratoses: a randomized clinical trial
Chemoradiotherapy with taxane is superior to conventional surgery and radiotherapy in the management of cutaneous angiosarcoma: a multicentre, retrospective study
Cost-effectiveness of topical imiquimod and fluorouracil vs. photodynamic therapy for treatment of superficial basal-cell carcinoma
A treatment for severe nodular acne: a randomized investigator-blinded, controlled, noninferiority trial comparing fixed-dose adapalene/benzoyl peroxide plus doxycycline vs. oral isotretinoin
Genetic variations of NLRP1 : susceptibility in psoriasis
Mutations in SMARCAD1 cause autosomal dominant adermatoglyphia and perturb the expression of epidermal differentiation-associated genes
Analysis of human β-papillomavirus and Merkel cell polyomavirus infection in skin lesions and eyebrow hair bulbs from a cohort of patients with chronic lymphocytic leukaemia
Vemurafenib skin phototoxicity is indirectly linked to ultraviolet A minimal erythema dose decrease
Ribosomal protein S6 is hyperactivated and differentially phosphorylated in epidermal lesions of patients with psoriasis and atopic dermatitis
A pyogenic granuloma treated with topical timolol
Severe flucloxacillin-induced acute generalized exanthematous pustulosis (AGEP), with toxic epidermal necrolysis (TEN)-like features: does overlap between AGEP and TEN exist? Clinical report and review of the literature
A case of tumour necrosis factor-α inhibitor- and rituximab-induced plantar pustular psoriasis that completely resolved with tocilizumab
Characterization of skin lesions induced by skin-tropic α- and β-papillomaviruses in a patient with epidermodysplasia verruciformis
A case of oral mucous membrane pemphigoid with IgG antibodies to integrin α6β4
Erythema annulare-like acantholytic dermatosis: a subset of pemphigus foliaceus
Subacute cutaneous lupus erythematosus induced by the new multikinase inhibitor pazopanib
Tattoos and coincidental skin conditions: the example of lymphomatoid papulosis
Association of hidradenitis suppurativa disease severity with increased risk for systemic comorbidities
Familial pachyonychia congenita with steatocystoma multiplex and multiple abscesses of the scalp due to the p.Asn92Ser mutation in keratin 17
Sunscreen adherence: proffer patient preference
Two cases of bilateral earlobe cutaneous pseudolymphoma
Sun exposure: perceptions and behaviours in outdoor workers
Hydroxycarbamide-induced cutaneous ulceration with a difference
Epidermolysis bullosa acquisita-like eruption with anticollagen VII autoantibodies induced by d-penicillamine in Wilson disease
Hidradenitis suppurativa fulminans: a clinically distinct phenotype?
Ultraviolet-induced linear IgA bullous dermatosis: a case report and literature survey
Trichorhinophalangeal syndrome type II due to a novel 8q23.3–q24.12 deletion associated with imperforate hymen and vaginal stenosis
Toxic epidermal necrolysis and natural remedies
The serum level of HMGB1 (high mobility group box 1 protein) is preferentially high in drug-induced hypersensitivity syndrome/drug reaction with eosinophilia and systemic symptoms
A case of pemphigus herpetiformis-like atypical pemphigus with IgG anti-desmocollin 3 antibodies
Lymphomatoid papulosis with 6p25.3 rearrangement: a further case of the newly described variant
Clinical evaluation of a T. rubrum -specific polymerase chain reaction and pandermatophyte polymerase chain reaction in the diagnosis of suspected onychomycosis in 183 Serbian patients
Treatment of chronic hepatitis with boceprevir leads to remission of porphyria cutanea tarda
Alternative treatment with calcipotriol plus betamethasone dipropionate gel in psoriasis vulgaris using a short-contact approach
Letter to the Editor concerning the article ‘Geographical ancestry is a key determinant of epidermal morphology and dermal composition’
Guideline vs. practice in procollagen-3-aminopeptide monitoring
Use of biologics in the treatment of hidradenitis suppurativa: a review of the Henry Ford Hospital experience
Linear immunoglobulin A disease and vancomycin: letter in reply
Clinicopathological characteristics of 270 patients with lentigo maligna and lentigo maligna melanoma: data from a German skin cancer centre
Radiation Therapy for Skin Cancer
News and Notices
Antitumour necrosis factor therapy promotes type I interferon-driven psoriasis-like skin inflammation : FC01
Autoinflammation may promote autoimmune responses of both CD4+ and CD8+ T cells in generalized pustular psoriasis : FC02
Imiquimod-induced psoriasis-like skin inflammation is alleviated in leptin-deficient mice : FC03
The psoriasis-associated chemokine scavenging receptor ACKR2 controls inflammatory T-cell migration and is regulated by tensile stress and microRNA-146 : FC04
The IκBζ protein is a downstream target of interleukin-17A and a key driver in the development of psoriasis : FC05
Secukinumab and the neutrophil—keratinocyte axis: a potential early target for the antiinterleukin-17a antibody : FC06
A novel T helper 17 cytokine mediates the high antiviral competence of psoriatic skin : FC07
Human beta-defensin 3 and its mouse orthologue murine beta-defensin 14 activate Langerhans cells and exacerbate psoriasis-like skin inflammation in mice : FC08
Shared inflammatory signatures between atherosclerotic plaque and psoriatic skin : FC09
‘I should have taken that further’: a mixedmethods study of missed opportunities in the cardiovascular risk assessment of patients with psoriasis : FC10
Cardiovascular risk assessment by cardiac computed tomography indicates more prevalent coronary artery disease in both severe psoriasis and severe atopic dermatitis : FC11
An investigation of brain inflammation in psoriasis : FC12
Genome-wide association analysis of psoriatic arthritis : FC13
LCE3B/LCE3C deletion and psoriasis-associated cytokines modulate the expression of late cornified envelope genes : FC14
Enhanced meta-analysis and replication studies identify five psoriasis susceptibility loci : FC15
Identification of known and novel coding variant associations utilising exome arrays: The International Psoriasis Council Exome Chip Project : FC16
Genetic and immunological characterization of generalized pustular psoriasis : towards genotype-phenotype correlations : FC17
Palmoplantar pustular psoriasis is associated with a missense variant in CARD14 in European patients : FC18
IL36RN mutations define a severe, early-onset subtype of generalized pustular psoriasis : FC19
Immune signatures of psoriasis : FC20
Pharmacogenomic signatures of response to etanercept therapy for psoriasis : FC21
A step towards personalized treatment in psoriasis: the therapeutic range of adalimumab serum concentrations established by means of a prospective daily practice cohort study : FC22
Comparative analysis of comorbidity in children with psoriasis and atopic eczema : FC23
In vivo characterization of vascular diseases in psoriasis through implementation of a multimodal imaging program : FC24
Psoriasis and the risk of stroke: a populationbased cohort study : FC25
Psoriasis and its association with anxiety and depression : FC26
Prevalence and comorbidities in adults with psoriasis compared with atopic dermatitis: analysis of health insurance data in Germany : FC27
Persistence with biological therapies for the treatment of moderate-to-severe psoriasis: a prospective observational study from the British Association of Dermatologists' Biologic Interventions Register (BADBIR) : FC28
Persistence of biological therapy in psoriatic disease: results from the Psoriasis Longitudinal Assessment and Registry : FC29
AMAGINE-1: a phase 3, randomized, double-blind, placebo-controlled study of brodalumab in subjects with psoriasis : FC30
Leptin-induced CXCL1 expression in fibroblasts may play a linking role between obesity and psoriasis : FC31
Pathological immune pathways in psoriasis are rapidly attenuated by tofacitinib treatment : FC32
Quality of psoriasis care in Germany 2013: first results of the national survey PsoHealth3 : FC33
The effect of tumour necrosis factor-α antagonist therapy on insulin resistance in patients with psoriasis with type 2 diabetes : P01
The correlation of clinical efficacy, serum trough levels and antidrug antibodies in patients with psoriasis treated with ustekinumab in a clinical practice setting : P02
Seasonal variation in psoriasis: a 3-year study utilizing the Physician's Global Assessment psoriasis severity scale : P03
A study of nail changes in various dermatoses : P04
Differential effects of systemic treatment and narrowband ultraviolet B therapy on elevated circulating cardiovascular risk markers in patients with psoriasis : P05
Apoptosis resistance in psoriatic epidermal keratinocytes : P06
The incidence of pulmonary arterial hypertension in psoriasis : P07
Transcriptional landscape of psoriasis provides further details for the pathophysiology : P08
Patient preferences for treatment of psoriasis with biologics: a discrete choice experiment : P09
Should the QuantiFERON test be part of standard examinations performed prior to cyclosporine A therapy? : P10
Bechterew disease and psoriasis vulgaris capilitii gravis treated with a therapeutic combination consisting of biologics and retinoids : P11
The effect of psoriasis treatment on body composition, components of metabolic syndrome and psoriatic arthritis : P12
Ustekinumab therapy inhibits T-lymphocyte motility : P13
Effect of ustekinumab on Psoriasis Area and Severity Index body regions, components and nail psoriasis scores in patients with moderate-tosevere psoriasis from the TRANSIT study, and correlation between changes in Psoriasis Area Severity Index body regions, components and Nail Psoriasis Severity Index scores, and Dermatology Life Quality Index scores : P14
The overexpression of several inflammation-, proliferation- and apoptosis-related microRNAs in the skin from patients with psoriasis : P15
Patients with psoriasis are insulin resistant : P16
Drivers of distress in psoriatic arthritis: a qualitative study : P17
Identifying patient-reported outcome measures for the clinical management of psoriasis : P18
Using creative methods to facilitate qualitative research with patients with psoriasis : P19
Developing content for a new patient-reported outcome measure for the clinical management of psoriasis : P20
Psoriasis, sleep and interleukin-17: is it a reality or just a dream? : P21
Effects of genistein on mRNA levels of AURKA, AURKB, EZH2 and FOXO1, the expressions of which are affected in psoriasis: a study on the human fibroblast culture model : P22
mRNA expression profiling in genistein-treated keratinocytes (HaCaT) as a potential tool for monitoring the treatment of psoriasis patients with isoflavone therapy : P23
Differences between adalimumab drug survival rates in Crohn disease, rheumatoid arthritis and psoriasis : P24
Early changes in mRNA expression in psoriatic skin during adalimumab treatment are not microRNAd riven : P25
Psoriasin (S100A7) is regulated by protein kinase C and contributes to keratinocyte differentiation by regulating the expression of epidermal differentiation markers : P26
Candidate gene variant genotypes for generalized pustular psoriasis suggest combined pathogenesis of autoinflammation and autoimmunity : P27
The prevalence of obesity is increased in patients with late- compared with early-onset psoriasis : P28
HLA-Cw6 polymorphisms may help predict response to biological therapy in patients with chronic plaque psoriasis : P29
Risk of developing cancer among patients with psoriasis compared with patients without psoriasis : P30
An examination of biological treatment groups of patients with psoriasis in a cohort of the Newfoundland and Labrador population : P31
Intraindividual genome expression analysis reveals opposing immune reaction in psoriasis and eczema : P32
Transit amplifying cells from psoriatic lesions carry the comorbidity signature : P33
TNFAIP3 rs610604 psoriasis predisposition single nucleotide polymorphism regulates IκB kinase-α binding to chromatin and sensitivity to tumour necrosis factor-α : P34
Biologics treatment discontinuation rates mainly due to treatment failure or adverse events in patients in Canada with moderate-to-severe plaque psoriasis : P35
Secukinumab administration by prefilled syringe maintains reduction in severity of plaque psoriasis over 52 weeks: results of the FEATURE trial : P36
Longitudinal treatment pathways for patients with moderate-to-severe plaque psoriasis in Canada: from conventional therapies to biological treatment and beyond : P37
Secukinumab administration by autoinjector maintains reduction in severity of plaque psoriasis over 52 weeks: results of the JUNCTURE trial : P38
Initial treatment with topical or oral systemic agents before biological therapy in patients with psoriatic arthritis: results from a Canadian clinical setting : P39
Characterization of a new pustular psoriasis gene : P40
Psoriasis as a complex long-term condition: what do healthcare practitioners understand? : P41
‘You look fine to me’: conceptualizing cardiovascular disease risk for people with psoriasis : P42
Secukinumab reverses disease-defining psoriasis histopathology while retaining full T-cell activation potential : P43
‘This is more stuff I’ve got to include in my life': the experience of patients with psoriasis of cardiovascular disease risk assessment - a qualitative study : P44
Talking to people with psoriasis about cardiovascular disease risk factors: techniques used in the practitioner-patient consultation : P45
Production of CCL20 and human β-defensin 2 is no different in keratinocytes cultured from healthy skin and uninvolved psoriasis skin : P46
Health promotion for patients with psoriasis: examining current signposting in U.K. health centres : P47
Genome-wide study of psoriasis in India : P48
Cytokine-mediated induction of mTORC1 signalling prevents proper differentiation of keratinocytes and contributes to the pathogenesis of psoriasis : P49
Does health message framing affect behavioural intentions in patients with psoriasis? An experimental study : P50
Psoriasis severity is partially explained by illness beliefs, mood and binge eating in overweight individuals : P51
Effects of apremilast on pruritus in patients with moderate-to-severe plaque psoriasis: results from the ESTEEM 1 and 2 trials : P52
Supporting lifestyle behaviour change for patients with psoriasis: assessing health professionals' core training competencies : P53
Long-term safety and tolerability of apremilast in patients with psoriasis: pooled safety analysis of two phase 3, randomized controlled trials (ESTEEM 1 and 2) : P54
A systems biological model of chronic plaque psoriasis captures dynamics of known treatments : P55
Dermatology Life Quality Index: a potential marker of exercise engagement in patients with psoriasis : P56
The p.Asp176His CARD14 variant is associated with generalized pustular psoriasis presenting with concurrent psoriasis vulgaris : P57
A case report of generalized pustular psoriasis of von Zumbusch associated with hypothyroidism : P58
Cardiovascular risk age, Framingham Risk and Systematic Coronary Risk Evaluation (SCORE) in patients with psoriasis and psoriatic arthritis : P59
Human leucocyte antigen Cw6 predisposes to clinical response to the inlterleukin-12/23 blocker ustekinumab: results of long-term treatment : P60
Network analysis of psoriasis cytokine pathways after treatment with four different biological therapeutics or candidates : P61
Itolizumab may be a safe and cost-effective biological option in the treatment of psoriasis: clinical experience in Indian patients : P62
Fumaric acid esters: from clinic to genes : P63
Psoriasis and the risk of myocardial infarction: a population-based cohort study : P64
The impact of tuberculosis chemoprophylaxis on patients with positive tuberculin skin test conversion, undergoing biological treatment for moderate-to-severe psoriasis : P65
mRNA expression of the T-cell receptor gamma-V gene family may help predict the efficacy of interleukin-17A blockade in psoriasis using ixekizumab : P66
‘You have to prioritize your own role’: a qualitative investigation of clinicians' beliefs about supporting patients with psoriasis with lifestyle management : P67
Interleukin-36 receptor antagonist is activated by a neutrophil protease: implication for a regulatory role of neutrophils in psoriasis : P68
Pilot data on using coronary artery calcium score to improve risk stratification in patients with moderate-to-severe psoriasis : P69
Early identification of response with methotrexate for moderate-to-severe psoriasis : P70
It is time to redefine psoriasis type I as three different types of psoriasis : P71
Superimposed linear psoriasis: a rare manifestation of a polygenic skin disorder : P72
Streptococcus-induced activation of circulating cutaneous lymphocyte-associated antigen-positive T and epidermal cells in human leucocyte antigen-Cw6+ patients: a predominant T helper (Th)17 response in patients with guttate psoriasis and Th1/Th17/Th9 in chronic plaque psoriasis responders : P73
PsoCom: development and validation of a screening tool for comorbidity in psoriasis : P74
miR-146a, a microRNA overexpressed in psoriasis, is a potent regulator of interleukin-1β-induced inflammatory responses in keratinocytes : P75
Interleukin (IL)-19 is a novel component of the pathogenetic IL-23/IL-17 pathway in psoriasis : P76
Adalimumab reduces the number of circulating and skin T helper 17 cells in psoriasis without a significant effect on regulatory T cells : P77
The importance of severity scores in monitoring patients with psoriasis undergoing phototherapy : P78
Effect of proactive treatment with topical calcipotriol on recurrence of psoriatic plaques : P79
Dysfunctional CARD18, a negative regulator of inflammasome activation, in psoriatic uninvolved epidermis may contribute to disease pathogenesis : P80
Vaccination in patients with psoriasis: what is the status of recommended vaccinations? : P81
Secukinumab treatment demonstrates a neutral effect on the lipid profile of subjects with moderate-to-severe plaque psoriasis in the 52-week randomized, double-blind, placebocontrolled, phase III FIXTURE study : P82
Value for money in treating psoriasis: a systematic review of full economic evaluations of psoriasis therapies : P83
Are there effects of tumour necrosis factor-α blockers on male fertility? : P84
Significant effects of patient educative training on psoriasis disease : P85
Primary care screening for cardiovascular risk factors in patients with psoriasis : P86
A highly sensitive and drug-tolerant immunogenicity screening assay for ixekizumab, an anti-interleukin-17A antibody, using an affinity capture elution approach : P87
Treatment goals and outcomes measurement in psoriasis routine care : P88
Influenza vaccination rate among patients with moderate-to-severe psoriasis in the German National Psoriasis Registry PsoBest : P89
Serum ferritin levels as an indicator of anaemia in patients with moderate-to-severe psoriasis compared with the general public : P90
Burden of scalp psoriasis in a tertiary referral psoriasis clinic in Singapore : P91
Interleukin-29 induces CXCR3 ligands and provokes T-cell infiltration into the skin : P92
Benefits of membership of the German Psoriasis Patient Association: a comparative quasiexperimental longitudinal study : P93
Methods used to measure patient preferences in psoriasis treatments and recommendations of the German IQWiG : P94
Psoriasis Area and Severity Index: a patientrelevant outcome in psoriasis care? : P95
Clinic to gene to clinic (a psoriasis journey: the first quarter century) : P96
Secukinumab, a novel anti-interleukin-17A antibody, exhibits low immunogenicity potential according to human in vitro assays : P97
Novel T-helper populations play an important role in psoriasis pathogenesis by producing granulocyte-macrophage colony-stimulating factor : P98
Multiple imputation methodology is reflective of secukinumab efficacy in real clinical practice: data from the FIXTURE and ERASURE studies in moderate-to-severe plaque psoriasis : P99
Serious infection events in the Psoriasis Longitudinal Assessment and Registry Study: current status of observations : P100
Regulating interleukin (IL)-10 and IL-17 expression, a novel role of human defensin-2 in psoriasis? : P101
An IKZF2+FOXP3+ regulatory T-cell subpopulation is more competitive than conventional population in psoriasis : P102
Secukinumab, a novel anti-interleukin-17A antibody, exhibits low immunogenicity during longterm treatment in subjects with psoriasis : P103
Aldara-induced psoriasis-like skin inflammation in tumour necrosis factor-α- and MK2-deficient mice : P104
Highly sensitive C-reactive protein and psoriasis : P105
Drug adherence to ustekinumab in the treatment of plaque psoriasis under daily life conditions: report from the Psoriasis Registry Austria : P106
Psychological distress in psoriasis outpatients is equivalent to that in oncology outpatients : P107
Modulation of metabolomic signature on biological treatment with etanercept in psoriasis : P108
IL36RN and CARD14 are not major genes in clinical phenotypes of pustular and nonpustular psoriasis : P109
The association between anxiety and depression with early- and late-onset psoriasis : P110
Deficiency of the local cortisol stress response pathway in psoriatic skin : P111
Five-year interim results from the ESPRIT 10-year postmarketing surveillance registry of adalimumab for moderate-to-severe psoriasis : P112
Disconnect between radiographic progression and skin or arthritic outcomes in patients with psoriatic arthritis treated with adalimumab : P113
Prioritizing the global research agenda in psoriasis: an International Psoriasis Council Delphi consensus exercise : P114
Keratolytic activity of a novel topical dimeticone formulation (LOYON®) compared with 10% salicylic acid oil in patients with psoriasis capitis : P115